REG - Novacyt S.A. - Holdings in Company

Novacyt SAAnnouncement

06/01/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230106:nRSF9738La&default-theme=true

RNS Number : 9738L  Novacyt S.A.  06 January 2023

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Holdings in Company

 

Paris, France and Camberley, UK - 6 January 2023 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces that it was notified by Biosynex SA ("Biosynex") on 5
January 2023 that, as at 3 January 2023, Biosynex's holding in the Company on
a voting and capital basis is 2.88% (2,030,916 shares).

 

For further information, please refer to www.novacyt.com
(http://www.novacyt.com) or contact:

 

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis (Joint Broker)

James Black / Freddie Barnfield / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) ;
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly serves
microbiology, haematology and serology markets as do its global partners,
which include major corporates.

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUNAUROAUARAR